miRNA Predictors of Pancreatic Cancer Chemotherapeutic Response: A Systematic Review and Meta-Analysis

Background: pancreatic cancer (PC) has increasing incidence and mortality in developing countries, and drug resistance is a significant hindrance to the efficacy of successful treatment. The objective of this systematic review and meta-analysis was to evaluate the association between miRNAs and response to chemotherapy in pancreatic cancer patients. Methods: the systematic review and meta-analysis was based on articles collected from a thorough search of PubMed and Science Direct databases for publications spanning from January 2008 to December 2018. The articles were screened via a set of inclusion and exclusion criteria based on the preferred reporting items for systematic review and meta-analysis (PRISMA) guidelines. Data was extracted, collated and tabulated in MS Excel for further synthesis. Hazard ratio (HR) was selected as the effect size metric to be pooled across studies for the meta-analysis, with the random effects model being applied. Subgroup analysis was also conducted, and the presence of publication bias in the selected studies was assessed. Publication bias of the included studies was quantified. Findings: of the 169 articles screened, 43 studies were included in our systematic review and 13 articles were included in the meta-analysis. Gemcitabine was observed to be the principal drug used in a majority of the studies. A total of 48 miRNAs have been studied, and 18 were observed to have possible contributions to chemoresistance, while 15 were observed to have possible contributions to chemosensitivity. 41 drug-related genetic pathways have been identified, through which the highlighted miRNA may be affecting chemosensitivity/resistance. The pooled HR value for overall survival was 1.603; (95% Confidence Interval (CI) 1.2–2.143; p-value: 0.01), with the subgroup analysis for miR-21 showing HR for resistance of 2.061; 95% CI 1.195–3.556; p-value: 0.09. Interpretation: our results highlight multiple miRNAs that have possible associations with modulation of chemotherapy response in pancreatic cancer patients. Further studies are needed to discover the molecular mechanisms underlying these associations before they can be suggested for use as biomarkers of response to chemotherapeutic interventions in pancreatic cancer.

[1]  Yaohuan Huang,et al.  Activating miRNA-mRNA network in gemcitabine-resistant pancreatic cancer cell associates with alteration of memory CD4+ T cells , 2020, Annals of translational medicine.

[2]  C. Pilarsky,et al.  Chemoresistance in Pancreatic Cancer , 2019, International journal of molecular sciences.

[3]  R. Jayaraj,et al.  Comment on, "Survival for HPV-positive oropharyngeal squamous cell carcinoma with surgical versus non-surgical treatment approach: A systematic review and meta-analysis". , 2019, Oral oncology.

[4]  S. Baxi,et al.  Commentary: Blood-Derived microRNAs for Pancreatic Cancer Diagnosis: A Narrative Review and Meta-Analysis , 2019, Front. Physiol..

[5]  R. Jayaraj,et al.  Conceptual interpretation of analysing and reporting of results on systematic review and meta-analysis of optimal extent of lateral neck dissection for well-differentiated thyroid carcinoma with metastatic lateral neck lymph nodes. , 2019, Oral oncology.

[6]  K. Gothandam,et al.  Comment on “Systematic Review and Meta-Analysis of Diagnostic Accuracy of miRNAs in Patients with Pancreatic Cancer” , 2018, Disease markers.

[7]  R. Jayaraj,et al.  Prognostic value of microRNAs in head and neck cancers: a systematic review and meta-analysis protocol , 2018, Systematic Reviews.

[8]  R. Jayaraj,et al.  Systematic review and meta-analysis of cancer studies evaluating diagnostic test accuracy and prognostic values: approaches to improve clinical interpretation of results , 2018, Cancer management and research.

[9]  R. Jayaraj,et al.  Systematic Review and Meta-analysis of the Prognostic Significance of miRNAs in Melanoma Patients , 2018, Molecular Diagnosis & Therapy.

[10]  R. Jayaraj,et al.  Systematic review and meta-analysis of risk-reductive dental strategies for medication related osteonecrosis of the jaw among cancer patients: Approaches and strategies , 2018, Oral Oncology.

[11]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[12]  Lianfang Zheng,et al.  MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma , 2018, Journal of Experimental & Clinical Cancer Research.

[13]  R. Jayaraj,et al.  Comment on ‘Prognostic biomarkers for oral tongue squamous cell carcinoma: a systematic review and meta-analysis’ , 2018, British Journal of Cancer.

[14]  Shuai Huang,et al.  miR-3656 expression enhances the chemosensitivity of pancreatic cancer to gemcitabine through modulation of the RHOF/EMT axis , 2017, Cell Death & Disease.

[15]  Xitao Wang,et al.  CXCR4/Let-7a Axis Regulates Metastasis and Chemoresistance of Pancreatic Cancer Cells Through Targeting HMGA2 , 2017, Cellular Physiology and Biochemistry.

[16]  A. Chaudhary,et al.  Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205. , 2017, Cancer letters.

[17]  J. Inazawa,et al.  miR-509-5p and miR-1243 increase the sensitivity to gemcitabine by inhibiting epithelial-mesenchymal transition in pancreatic cancer , 2017, Scientific Reports.

[18]  F. Liu,et al.  miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in pancreatic cancer , 2017, Acta biochimica et biophysica Sinica.

[19]  I. Herr,et al.  microRNA-210 overexpression inhibits tumor growth and potentially reverses gemcitabine resistance in pancreatic cancer. , 2017, Cancer letters.

[20]  Y. Takeda,et al.  MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma , 2017, Scientific Reports.

[21]  Hao Hu,et al.  micorRNA-101 silences DNA-PKcs and sensitizes pancreatic cancer cells to gemcitabine. , 2017, Biochemical and biophysical research communications.

[22]  Rong Liu,et al.  Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis , 2016, Cancer Chemotherapy and Pharmacology.

[23]  Minmin Shi,et al.  GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer. , 2016, Cancer letters.

[24]  Wei Li,et al.  Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling , 2016, Oncogene.

[25]  I. Herr,et al.  MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer. , 2016, Cancer letters.

[26]  P. Han,et al.  miR-203 promotes proliferation, migration and invasion by degrading SIK1 in pancreatic cancer. , 2016, Oncology reports.

[27]  Peng Xu,et al.  MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20. , 2016, Acta biochimica et biophysica Sinica.

[28]  J. Marshall,et al.  Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer , 2016, Oncology letters.

[29]  D. Ichikawa,et al.  Plasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer , 2015, British Journal of Cancer.

[30]  Min Wang,et al.  Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway , 2015, Oncotarget.

[31]  Y. Huang,et al.  Upregulation of microRNA‑138‑5p inhibits pancreatic cancer cell migration and increases chemotherapy sensitivity. , 2015, Molecular medicine reports.

[32]  Jian-hua Zhang,et al.  miR-15b promotes epithelial-mesenchymal transition by inhibiting SMURF2 in pancreatic cancer. , 2015, International journal of oncology.

[33]  Menghong Sun,et al.  MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine , 2015, Oncotarget.

[34]  G. Zhao,et al.  Ectopic expression of miR-494 inhibited the proliferation, invasion and chemoresistance of pancreatic cancer by regulating SIRT1 and c-Myc , 2015, Gene Therapy.

[35]  T. Keck,et al.  ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat , 2015, EMBO molecular medicine.

[36]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[37]  J. Ellwart,et al.  Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer , 2015, Targeted Oncology.

[38]  Min Wang,et al.  MicroRNA-100 regulates pancreatic cancer cells growth and sensitivity to chemotherapy through targeting FGFR3 , 2014, Tumor Biology.

[39]  S. Kulp,et al.  Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells. , 2014, Carcinogenesis.

[40]  E. Giovannetti,et al.  Molecular Mechanisms Underlying the Role of MicroRNAs in the Chemoresistance of Pancreatic Cancer , 2014, BioMed research international.

[41]  H. Eguchi,et al.  MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer , 2014, British Journal of Cancer.

[42]  L. You,et al.  MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis , 2014, Oncotarget.

[43]  Gopal Chakrabarti,et al.  miR-17-5p Downregulation Contributes to Paclitaxel Resistance of Lung Cancer Cells through Altering Beclin1 Expression , 2014, PloS one.

[44]  Burton B. Yang,et al.  MicroRNA-in drug resistance , 2014, Oncoscience.

[45]  Wei-yi Huang,et al.  MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[46]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[47]  R. Qin,et al.  Direct targeting of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma tumourigenesis and metastasis , 2013, British Journal of Cancer.

[48]  H. Eguchi,et al.  MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-catenin signaling pathway in pancreatic cancer cells. , 2013, International journal of oncology.

[49]  Chung-Pin Li,et al.  A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer , 2013, Cancer Chemotherapy and Pharmacology.

[50]  Fenggui Wei,et al.  miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer , 2013, Molecular Cancer.

[51]  R. Mahato,et al.  miRNA profiling in pancreatic cancer and restoration of chemosensitivity. , 2013, Cancer letters.

[52]  H. Eguchi,et al.  miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1 , 2013, British Journal of Cancer.

[53]  Kun Wang,et al.  The serum miR‐21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR‐21 expression confers chemoresistance by targeting FasL , 2013, Molecular oncology.

[54]  H. Ueno,et al.  Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Enrica Martinelli,et al.  MiR-200c and HuR in ovarian cancer , 2013, BMC Cancer.

[56]  J. M. Thomson,et al.  Differential Processing of let-7a Precursors Influences RRM2 Expression and Chemosensitivity in Pancreatic Cancer: Role of LIN-28 and SET Oncoprotein , 2013, PloS one.

[57]  G. Dranoff,et al.  Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.

[58]  Xi Chen,et al.  Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. , 2012, Clinical chemistry.

[59]  M. Büchler,et al.  Pancreatic Cancer Surgery in the New Millennium: Better Prediction of Outcome , 2011, Annals of surgery.

[60]  Simone Brabletz,et al.  The ZEB1/miR‐200 feedback loop controls Notch signalling in cancer cells , 2011, The EMBO journal.

[61]  K. Ohuchida,et al.  MicroRNA miR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion , 2010, Cancer biology & therapy.

[62]  Jia Yu,et al.  miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. , 2010, Cancer research.

[63]  Ugo Boggi,et al.  MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. , 2010, Cancer research.

[64]  Yong-Tae Kim,et al.  Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer , 2010, PloS one.

[65]  J Ma,et al.  MicroRNA and drug resistance , 2010, Cancer Gene Therapy.

[66]  Zhiwei Wang,et al.  Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. , 2010, Cancer research.

[67]  Jing Wen,et al.  CD44‐positive cells are responsible for gemcitabine resistance in pancreatic cancer cells , 2009, International journal of cancer.

[68]  Ann M. Killary,et al.  MicroRNAs in Plasma of Pancreatic Ductal Adenocarcinoma Patients as Novel Blood-Based Biomarkers of Disease , 2009, Cancer Prevention Research.

[69]  Zhiwei Wang,et al.  Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. , 2009, Cancer research.

[70]  P. Catalano,et al.  Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[72]  S. Nordeen,et al.  MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents , 2009, Molecular Cancer Therapeutics.

[73]  K. Ohuchida,et al.  MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance , 2009, Molecular Cancer Therapeutics.

[74]  Qizhi Yao,et al.  Profiling of 95 MicroRNAs in Pancreatic Cancer Cell Lines and Surgical Specimens by Real-Time PCR Analysis , 2009, World Journal of Surgery.

[75]  Zhiwei Wang,et al.  Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. , 2009, Cancer research.

[76]  Xiuping Liu,et al.  Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. , 2008, Biochemical pharmacology.

[77]  Wendy Frankel,et al.  MicroRNA-21 is Overexpressed in Pancreatic Cancer and a Potential Predictor of Survival , 2008, Journal of Gastrointestinal Surgery.

[78]  Olga Kovalchuk,et al.  Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin , 2008, Molecular Cancer Therapeutics.

[79]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[80]  H. Tagawa,et al.  Synergistic action of the microRNA‐17 polycistron and Myc in aggressive cancer development , 2007, Cancer science.

[81]  W. Scheithauer,et al.  Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  Thomas D. Schmittgen,et al.  Expression profiling identifies microRNA signature in pancreatic cancer , 2006, International journal of cancer.

[84]  K. Syrigos,et al.  A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer , 2006, British Journal of Cancer.

[85]  Kathryn A. O’Donnell,et al.  c-Myc-regulated microRNAs modulate E2F1 expression , 2005, Nature.

[86]  M. Reni,et al.  Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. , 2005, The Lancet. Oncology.

[87]  D. Wagener,et al.  Weekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma: a phase II study of the EORTC GastroIntestinal Tract Cancer Cooperative Group. , 2004, European journal of cancer.

[88]  Daniel G Haller,et al.  Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  H. Friess,et al.  Acquired Resistance of Pancreatic Cancer Cells towards 5-Fluorouracil and Gemcitabine Is Associated with Altered Expression of Apoptosis-Regulating Genes , 2002, Oncology.

[90]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[91]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[92]  M. Dimopoulos,et al.  Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  J. Verweij,et al.  Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[94]  T. Fleming,et al.  A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. , 1985, JAMA.

[95]  H. Choi,et al.  Non-thermal Plasma-activated Medium Induces Apoptosis of Aspc1 Cells Through the ROS-dependent Autophagy Pathway , 2019, In Vivo.

[96]  P. Smooker,et al.  Systematic review and meta-analysis protocol for Fasciola DNA vaccines , 2018 .

[97]  L. Wiebe.  A myriad of symptoms: new approaches to optimizing palliative care of patients with advanced pancreatic cancer. , 2012, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[98]  Xi Chen,et al.  Role of microRNA in anticancer drug resistance , 2010, International journal of cancer.

[99]  Shadan Ali,et al.  Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. , 2010, American journal of translational research.

[100]  H. Taubert,et al.  Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival , 2010, International journal of cancer.

[101]  T. Eberlein.  Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial , 2008 .